Form 4: Cyclo Therapeutics CEO N. Scott Fine Acquires Stock Options
SEC Form 4 Filing
N. Scott Fine, CEO of Cyclo Therapeutics, Inc., reports the acquisition of stock options.
Summary
- N. Scott Fine, the CEO of Cyclo Therapeutics, Inc., filed a Form 4 with the SEC.
- The filing reports a transaction that occurred on June 3, 2024.
- Fine acquired 266,354 stock options with an exercise price of $1.28.
- The options vest over a one-year period in equal quarterly installments and expire on June 3, 2034.
- Following the transaction, Fine directly owns 266,354 derivative securities.
Sentiment
Score: 6
Explanation: Neutral sentiment. The document simply reports a stock option grant, which is a common practice. It doesn't inherently indicate positive or negative performance.
Positives
- The CEO's acquisition of stock options could be seen as a positive sign, indicating confidence in the company's future performance.
Industry Context
Form 4 filings are standard practice and provide transparency into the transactions of company insiders, allowing investors to monitor potential alignment of interests between management and shareholders.
Stakeholder Impact
- The acquisition of stock options by the CEO may align his interests more closely with those of shareholders, potentially encouraging decisions that benefit the company's long-term value.
Key Dates
| Date | Description |
|---|---|
| 06/03/2024 | Date of the stock option acquisition. |
| 06/03/2034 | Expiration date of the stock options. |
| 06/05/2024 | Date of signature on the Form 4 filing. |
Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.